Navigation Links
FDA Approves Abbott's XIENCE(TM) V Drug Eluting Stent
Date:7/2/2008

our and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA).

Abbott also supplies a private-label version of XIENCE V to Boston Scientific called the PROMUS(TM) Everolimus-Eluting Coronary Stent System. PROMUS is designed and manufactured by Abbott and supplied to Boston Scientific as part of a distribution agreement between the two companies.

Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its antiproliferative properties.

Additional information about XIENCE V, including important safety and effectiveness information, is available online at http://www.xiencev.com.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 68,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.

*Event rates are based
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. FDA Approves ACIPHEX(R) (rabeprazole sodium) 20 mg for Short-Term Treatment of GERD in Adolescents
2. FDA Approves CONCERTA(R) (methylphenidate HCI) Extended-release Tablets for Treatment of ADHD (Attention Deficit Hyperactivity Disorder) in Adults
3. FDA Approves Quark IND for DGFi, an siRNA Therapeutic Based on Silence Therapeutics Unique Proprietary Chemistry
4. Big Win for Biodiesel: ASTM Approves New Biodiesel Blend Specifications
5. FDA Approves GlaxoSmithKlines AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
6. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
7. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
8. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
9. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
10. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
11. Medicare Approves in Home Sleep Apnea Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2015)... (PRWEB) March 31, 2015 Lighthouse ... firm with operations in California, Oregon, Washington and ... of its Merger and Acquisition (M&A) Integration Services ... Adams, VP Client Services and M&A Integration Practice ... that the vast majority of M&A initiatives fail ...
(Date:3/30/2015)... 2015  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), ... Inc. has added another internationally recognized researcher to ... an internationally recognized researcher in bio-inspired materials and ... Peking University, China , Professor ... of North Carolina, Chapel Hill. Following a postdoctoral ...
(Date:3/30/2015)... , March 30, 2015    Intrexon Corporation ... synthetic biology, and Merck Serono, the biopharmaceutical business ... , today announced an exclusive strategic collaboration and ... Receptor T-cell (CAR-T) cancer therapies. This collaboration advances ... therapies that modulate the immune system,s natural ability ...
(Date:3/30/2015)... -- Richmond Pharmacology nimmt weltweit den ... das erste Zentrum weltweit, das in Zusammenarbeit mit ... London in einer weltweiten ... einem Patienten begonnen hat. Das Therapeutikum wurde für ... einer seltenen Herz- und Nervenkrankheit. ...
Breaking Biology Technology:Lighthouse Information Systems, Inc., Announces Addition of M&A Integration Services 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4
... decades X-ray crystallography has been fundamental in the development ... the structure and function of many biological molecules, including ... However, in order to obtain good data, large ... to grow. There also is the problem that ...
... SOUTH SAN FRANCISCO, Calif., Feb. 21, 2012 Onyx Pharmaceuticals, Inc. ... at four investor conferences in February and March. ... 2012 Citi Global Healthcare Conference on Monday, February 27, 2012 at ... Cowen and Company 32nd Annual Health Care Conference Onyx ...
... Inc. (Nasdaq: CDXS ), a developer of ... chemicals, and pharmaceutical intermediates, today announced that Peter Strumph, ... Jefferies Global Clean Technology Conference, to be held in ... 1:45 p.m. ET. A live webcast and replay will ...
Cached Biology Technology:Scientists learn how to 'out run damage' with imaging technique 2Onyx Pharmaceuticals to Present at Upcoming Investor Conferences 2
(Date:3/12/2015)... Calif. , March 12, 2015 WHEN:Tuesday, ... Complimentary Registration here: http://bit.ly/1G7Os0L . SPEAKERS: , ... Aravind SeshagiriPhoto - http://photos.prnewswire.com/prnh/20150311/181111 ... order to compete in several different markets and ... is currently witnessing an uptrend. ...
(Date:3/10/2015)... 10, 2015   Tute Genomics , pioneer in ... by next-generation sequencing company PrimBio Research Institute ... targeted gene panel interpretation. PrimBio, a certified ... most current technologies to support the work of experts ... offers two types of exome sequencing services: 1) Targeted ...
(Date:3/2/2015)... 2, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced a new implementation of ... enable rapid and secure transactions and reliable identification ... is a turnkey solution providing mouse and keyboard ... integrate fingerprint ID solutions into their product offerings, ...
Breaking Biology News(10 mins):Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 2Biometrics Key to Future Growth in Healthcare, Retail and Financial Markets 3PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 2PrimBio Research Selects Tute as Whole Exome Analysis Provider, Creating Integrated, End-to-End Solution for Next-Generation Sequencing & Data Analysis 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
... Soybean production has continued to increase in the Northeast ... the crop and many experienced growers planting alongside corn crops. ... with a corn planter in 30-inch rows instead of 7.5-inch ... a Cornell University scientist, investigated the response of two soybean ...
... L. Boren announced today that OU is establishing an ... expertise to benefit Oklahoma and the nation, including emerging ... led by a national expert, who will be appointed ... million gift from Corix, a multi-utility infrastructure company, which ...
... grant totaling $2.2 million shows how the University of ... using technology to advance the cutting-edge field of personalized ... their genetic make-up. The grant also highlights the ... Institute (CCTSI) to bring scientific discoveries to the bedside ...
Cached Biology News:OU establishes a new water and sustainability institute 2OU establishes a new water and sustainability institute 3Personalizing medicine 2Personalizing medicine 3
...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
... Amplification Grade digests single- ... oligodeoxyribonucleotides. The specific activity ... I Amplification Grade is ... for absence of RNase ...
Biology Products: